Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group.

Davi, Frédéric; Delecluse, Henri Jacques; Guiet, Pascal; Gabarre, Jean; Fayon, A; Gentilhomme, O; Felman, Pascale; Bayle, C; Berger, F; Audouin, J; Bryon, Paul‐André; Diébold, J; Raphaël, Martine

doi:10.1200/jco.1998.16.12.3788

Cited by 120 publications

(64 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13 Patients with HIV-BL closely resemble the general BL population in terms of stage, marrow involvement (33% to 35%), CNS involvement (17% to 19%), 14 and histology. 15 Prior to HAART, combination chemotherapy was less successful for patients with HIV-associated NHL than for HIV-negative patients with similar NHL histopathology. Early deaths were often the result of opportunistic infection.…”

Section: Introductionmentioning

confidence: 99%

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

Noy

Lee

Cesarman

et al. 2015

Blood

View full text Add to dashboard Cite

• We report the first dedicated prospective study in HIV-Burkitt lymphoma demonstrating safety and efficacy in a multiinstitutional setting.• We offer a new therapeutic option by modifying an existing regimen and making it much less toxic.The toxicity of dose-intensive regimens used for Burkitt lymphoma prompted modification of cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for HIV-positive patients. We added rituximab, reduced and/or rescheduled cyclophosphamide and methotrexate, capped vincristine, and used combination intrathecal chemotherapy. Antibiotic prophylaxis and growth factor support were required; highly active antiretroviral therapy (HAART) was discretionary. Thirteen AIDS Malignancy Consortium centers enrolled 34 patients from 2007 to 2010. Median age was 42 years (range, 19-55 years), 32 of 34 patients were high risk, 74% had stage III to IV BL and CD4 count of 195 cells per mL (range, 0-721 cells per mL), and 5 patients (15%) had CD4 <100 cells per mL. Twenty-six patients were receiving HAART; viral load was <100 copies per mL in 12 patients. Twenty-seven patients had at least one grade 3 to 5 toxicity, including 20 hematologic, 14 infectious, and 6 metabolic. None had grade 3 to 4 mucositis. Five patients did not complete treatments because of adverse events. Eleven patients died, including 1 treatment-related and 8 disease-related deaths. The 1-year progressionfree survival was 69% (95% confidence interval [CI], 51%-82%) and overall survival was 72% (95% CI, 53%-84%); 2-year overall survival was 69% (95% CI, 50%-82%). Modifications of the CODOX-M/IVAC regimen resulted in a grade 3 to 4 toxicity rate of 79%, which was lower than that in the parent regimen (100%), without grade 3 to 4 mucositis. Despite a 68% protocol completion rate, the 1-year survival rate compares favorably with 2 studies that excluded HIV-positive patients. This trial was registered at http:// clinicaltrials.gov as #NCT00392834. (Blood. 2015;126(2):160-166)

show abstract

Section: Introductionmentioning

confidence: 99%

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

Noy

Lee

Cesarman

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

“…A recent review of 75 adults with BL (46 HIV-positive) found no difference between HIV-positive and HIV-negative patients in terms of disease stage, BM (33-35%) and CNS (17-19%) involvement, 14 and histology. 15 The optimal treatment for adult patients with HIV-associated BL is not clear. In the era before highly active antiretroviral therapy (HAART), combination chemotherapy was less successful for patients with HIV-associated NHL than for HIV-negative patients with similar NHL histopathology.…”

mentioning

confidence: 99%

Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma

Wang

Straus

Teruya‐Feldstein

et al. 2003

Cancer

147

View full text Add to dashboard Cite

BACKGROUNDIn the era of highly active antiretroviral therapy (HAART), standard‐dose chemotherapy for human immunodeficiency virus (HIV)‐associated diffuse large B‐cell lymphoma is becoming the standard of care. In contrast, the safety and efficacy of intensive regimens have not been established for Burkitt lymphoma (BL), a highly aggressive lymphoma for which moderate‐dose chemotherapy is substandard in the HIV‐negative population.METHODSTo evaluate the feasibility of intensive chemotherapy in HIV‐associated BL, the authors retrospectively reviewed 14 HIV‐positive adults with BL treated at their center between 1988 and 2000. Eight patients were treated between 1996 and 2000 with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC), one of the currently preferred intensive‐dose chemotherapy regimens for BL. Six received other chemotherapy. Outcomes were compared with those of 24 HIV‐negative adult patients with BL who had similar patient characteristics and were treated concomitantly (13 with CODOX‐M/IVAC; 11 with other regimens).RESULTSOf the 14 HIV‐positive patients, 63% had a complete response after CODOX‐M/IVAC treatment, compared with 67% of patients receiving other chemotherapy. The 2‐year event‐free survival (EFS) rates were 60% and 60% after CODOX‐M/IVAC or other regimens, respectively. Similar outcomes were seen despite the fact that 88% of CODOX‐M/IVAC‐treated HIV‐positive patients had Stage IV disease, compared with one‐third of HIV‐positive patients treated with other chemotherapy. HIV status did not adversely affect long‐term EFS independent of the treatment regimen (P = 0.88). When EFS was evaluated according to chemotherapy regimen independent of HIV status, CODOX‐M/IVAC was found to be associated with improved EFS (P = 0.05) in all patients, and particularly those at high risk. HIV‐positive patients treated with CODOX‐M/IVAC tolerated chemotherapy well with similar rates of myelosuppression and infectious complications as HIV‐negative patients.CONCLUSIONSThe current nonrandomized retrospective study suggested that intensive chemotherapy with CODOX‐M/IVAC is feasible and well tolerated in HIV‐positive adults with BL. In the post‐HAART era, intensive chemotherapy such as CODOX‐M/IVAC may be appropriate in all adult patients with BL, and especially those with poor prognostic factors, regardless of HIV status. Cancer 2003;98:1196–205. © 2003 American Cancer Society.DOI 10.1002/cncr.11628

show abstract

“…In contrast with the African tumors in jaw, maxilla and orbital bones, this sporadic form involving the abdomen, typically the ileocecal region, and rarely involving orbital or ocular structures 10 . Originally the BL immunocompromised variant was described in patients with AIDS [11][12][13] . The infection by Epstein-Barr virus has been implicated in BL, being positive in 20% of sporadic cases, 40% in cases and as high as 95% in the endemic form [9][10][11] .…”

Section: Discussionmentioning

confidence: 99%

“…Originally the BL immunocompromised variant was described in patients with AIDS [11][12][13] . The infection by Epstein-Barr virus has been implicated in BL, being positive in 20% of sporadic cases, 40% in cases and as high as 95% in the endemic form [9][10][11] . One large study has reported that cases with positive Epstein-Barr antibody had better outcomes [11][12] .…”

Section: Discussionmentioning

confidence: 99%

“…The infection by Epstein-Barr virus has been implicated in BL, being positive in 20% of sporadic cases, 40% in cases and as high as 95% in the endemic form [9][10][11] . One large study has reported that cases with positive Epstein-Barr antibody had better outcomes [11][12] . BL is associated with c-myc translocation from chromosome 8 to 14, and this was observed in 66% of patients with orbital BL in some series.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Orbital Burkitt Lymphoma in an Immunocompetent Pediatric Patient

Feria-Anzaldo¹,

Ramirez²,

Andrade³

et al. 2017

ARC Journal of Surgery

View full text Add to dashboard Cite

Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group.

Abstract: BLL is a frequent entity among AIDS lymphomas and should be considered as a morphologic variant of BL in the context of severe immunodepression that occurs in HIV-infected patients.

Cited by 120 publications

References 0 publications

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma

Orbital Burkitt Lymphoma in an Immunocompetent Pediatric Patient

Contact Info

Product

Resources

About